Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enovis Corporation Common Stock (NY:ENOV)

21.69 -0.08 (-0.37%)
Streaming Delayed Price Updated: 10:35 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enovis Corporation Common Stock

News headline image
Enovis Debuts New Foot & Ankle Offerings at the AOFAS Annual Meeting
New solutions in Percutaneous and Open Bunion procedures, External Fixation, and Patient Specific Instrumentation, will be featured as part of the company’s growing evidence based, high tech... 
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis to Participate in Upcoming Investor Conferences
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis Announces Second Quarter 2023 Results and Raises Full-Year Outlook
From Enovis Corporation
Via GlobeNewswire
News headline image
Looking Into Enovis's Return On Invested Capital ↗
 
Via Benzinga
News headline image
Enovis Beats Q1 Earnings Estimates, Raises 2023 Guidance ↗
  
Via Benzinga
News headline image
Enovis: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Outlook For Enovis ↗
 
Via Benzinga
News headline image
Enovis to Host Second Quarter 2023 Results Conference Call on August 3rd
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis™ Recognized as One of America’s Greatest Workplaces 2023 by Newsweek
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis™ Completes Acquisition of Novastep®
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis Above-Market Growth Potential Surge Would Come from Market Share Gains and Accretive Acquisitions: Analyst ↗
Needham initiated coverage on Enovis Corp (NYSE: ENOV) with a Buy and a price target of $70, noting that the company can sustain above-market growth in its Reconstructive segment via market share gains... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023 ↗
 
Via Benzinga
News headline image
Enovis to Participate in Investor Conferences in June
From Enovis Corporation
Via GlobeNewswire
News headline image
3 Dividend Stocks That Are Raising Their Payouts ↗
Earnings have been remarkably resilient despite higher prices. Here are three dividend stocks that are increasing payouts as a result. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023 ↗
 
Via Benzinga
News headline image
Hyatt Hotels To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Friday ↗
Wells Fargo raised the price target for Enovis Corporation (NYSE: ENOV) from $55 to $67. Wells Fargo analyst Vik Chopra upgraded the stock from Equal-Weight to Overweight. Enovis shares rose 1.9% to... 
Via Benzinga
News headline image
This Analyst With 83% Accuracy Rate Sees Around 11% Upside In Texas Roadhouse - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts ↗
U.S stocks closed higher on Friday, with the Dow Jones jumping more than 500 points during the session. 
Via Benzinga
News headline image
Enovis Announces First Quarter 2023 Results
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis to Host First Quarter 2023 Results Conference Call on May 4th
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis to Acquire Novastep
Strengthens Foot and Ankle Portfolio with Leading Minimally Invasive Surgery (MIS) Platform, including MIS Bunion System and Furthers Global Expansion Strategy 
From Enovis Corporation
Via GlobeNewswire
News headline image
Top 5 Health Care Stocks That Preparing To Pump This Quarter ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Enovis Announces Board Leadership Transition
CEO Matt Trerotola to be named Chair and Director Sharon Wienbar to become Lead Independent Director following retirement of current Chair Mitchell P. Rales at 2023 Annual Meeting 
From Enovis Corporation
Via GlobeNewswire
News headline image
ENOVIS™ Showcases Next Generation of Medical Technology at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting
Medtech Leader Highlights Power of Collaboration in Its Continued Success and Innovation 
From Enovis Corporation
Via GlobeNewswire
News headline image
Newsweek Names Enovis™ as One of America’s Greatest Workplaces for Diversity 2023
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis Announces Fourth Quarter and Full Year 2022 Results
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis to Host Fourth Quarter and Full Year 2022 Conference Call on February 23rd
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis™ to Showcase Latest Innovations and Growing Foot & Ankle Portfolio at ACFAS 2023
With innovative offerings spanning across foot and ankle indications, Enovis will highlight its latest products including knotless suture anchors, bone fixation systems and disruptive NiTiNOL... 
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis Expands Foot & Ankle Portfolio’s DynaClip® Family by Introducing Procedure-Specific Staples
Innovative new staples combine strength with unmatched, sustained dynamic compression for mid-foot and first MTP joint fusions 
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Enovis Corporation
Via GlobeNewswire
News headline image
Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR® Ankle
The approval of the STAR PSI System marks an impactful milestone by allowing surgeons to provide a personalized pre-operative plan for their total ankle replacement patients 
From Enovis Corporation
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.